Identifying and treating depression, including increasing physical activity, may improve quality of life and reduce cardiovascular disease and death in African Americans, according to reports presented at the American Heart Association’s 2009 Conference on Nutrition, Physical Activity and Metabolism.
In one study, researchers in the Jackson Heart Study (JHS) (more…)
A study in the February 25 issue of JAMA reveals that low- income diabetic women who are pregnant or new mothers, have almost double the risk of suffering from depression during and after pregnancy, than women without diabetes.
In the perinatal period, usually known as the last few months of pregnancy and the year following childbirth, at least 10 to 12 percent of new mothers are affected (more…)
A new study has revealed the most commonly prescribed medication for Australian women is antidepressants.
The study, by researchers from Australian Longitudinal Study on Women’s Health (ALSWH).
Pharmaceutical Benefits Scheme and Medicare data were linked to survey data to examine claims and costs of medications and other health care resources.
Buy (more…)
Your mother’s wrinkles - or lack there of, may not be the best predictor of how you’ll age. In fact, a new study claims just the opposite. Buy clomid pills The study, involving identical twins, suggests that despite genetic make-up, certain environmental factors can add years to a person’s perceived age. Results just published (more…)
CeNeRx BioPharma,
Inc., a clinical stage company developing and commercializing innovative
treatments for diseases of the central nervous system, announced that
it has initiated a Phase II clinical trial for its lead product candidate
Tyrima(TM) for the treatment of major depressive (more…)
Images of the brain’s fastest signals reveal an electromagnetic marker that predicts a patient’s response to a fast-acting antidepressant, researchers have discovered.
"Such biomarkers that identify who will benefit from a new class of antidepressants could someday minimize trial-and-error prescribing and speed delivery of care for what can be a life-threatening (more…)
Valdoxan® today received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with Major Depressive Episodes (MDE).1
Valdoxan is an innovative approach to the treatment of MDE and has demonstrated convincing efficacy in depressed patients with moderate-severe depression2, offering new hope (more…)
The news about antidepressant medications over the past several years has been mixed. The bad news from large multicenter studies such as STAR*D is that current antidepressant medications are effective, but not as effective as one might hope. Thus, there is a significant need for new treatment mechanisms for depression. On that front, there has been mixed news as well. One of the most exciting new drugs (more…)
The American College of Physicians is publishing a new guideline for the treatment of depression in Annals of Internal Medicine. ACP found no substantial differences in efficacy or quality of life among "second-generation" antidepressants used to treat depressive (more…)
A new study shows that antidepressant drugs which only affect serotonin, often used as first choice treatments, may not be best for depression in people with Parkinson’s disease. The new research is published in the December 17, 2008, (more…)
Research published by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has added to the evidence base on treatment for adolescents who are clinically depressed. The researchers found that for adolescents with moderate to severe major depression, the addition (more…)
Millions of patients with treatment-resistant clinical depression, who have struggled for years with disability and how to cope with their condition, now have an option that could help them lead more productive and successful lives.
The NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy system, developed by Neuronetics, Inc. and initiated by research at the Medical University of South Carolina (MUSC), is the first and only approved (more…)
Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement. However, recent reports also suggest that antidepressants might, in some rare cases, actually worsen suicidal tendencies instead of alleviating them. As a consequence, (more…)
Clinicians and researchers from around the world attended this week’s 8th International Forum on Mood and Anxiety disorders in Vienna, Austria to discuss the latest advances in the treatment of mood disorders.
A wide range of topics were included in this year’s programme, highlighting the position of IFMAD (more…)
Women who took the antidepressant fluoxetine during the first three months of
pregnancy gave birth to four times as many babies with heart problems as women
who did not and the levels were three times higher in women taking paroxetine.
Although some of the conditions were serious, others were not severe and (more…)
GPs prescribe lower volumes of antidepressants in areas with more Black or South Asian people, suggesting possible disparities in the provision of care.
The study, published in the September issue of the British Journal of Psychiatry, also reveals that higher volumes of antidepressants are prescribed by general practices (more…)
Although complete nonresponse in depression treatment is considered to be a major problem in clinical practice, research (more…)
Patients who experience a range of ear, nose, and throat-related health problems exhibited a greater prevalence of depression than is observed in the general population, says new research presented at the 2008 American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO in Chicago, IL.
In any given one-year period, approximately (more…)
Voluntary physical activity does not appear to cause a reduction in anxiety and depression, but exercise and mood may be associated through a common genetic factor, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
In the general population, regular exercise is associated with reduced anxious and depressive symptoms, (more…)
Buy ultram without prescription Recent media coverage has questioned the prescription and safety of a class of antidepressants called Selective Serotonin Reuptake Inhibitors (SSRIs) in children and adolescents.
"General practitioners are a critical part of the mental health care system in Australia and are often the first point (more…)
Prescriptions filled for antidepressant drugs increased from 154 million in 2002 to 170 million in 2005, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Among the prescriptions (not including refills) which were written after patients talked with doctors in-person or over the phone. AHRQ data (more…)
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. (more…)
Patients suffering from major depression are at an increased risk for cardiovascular disease, but treating these patients with medication can greatly reduce the risk, according to new findings by researchers at the (more…)
TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced that it has completed an agreement with the Centre for Addiction and Mental Health (CAMH) in Ontario, (more…)
Intra-Cellular Therapies, Inc., announced additional preclinical data from its ongoing development
programs for ITI-007, the Company’s first-in-class dual 5HT2A receptor
antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722,
a low-dose formulation of ITI-007, which are in development for
schizophrenia and sleep disorders, respectively. These new data demonstrate
ITI-007 (more…)
Powered by WordPress